

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 50 (Issue 1299)
November 17, 2008

www.medicalletter.org

Safety of SSRIs in Pregnancy

Depression occurs in up to 20% of pregnant women, and the use of selective serotonin reuptake inhibitors (SSRIs) in these women has been increasing.¹ Maternal depression has itself been associated with intrauterine growth problems and low birth weight, so the risks of exposure to antidepressants during pregnancy must be weighed against the risks of untreated depression, which also include self-harm, poor bonding and poor parenting. SSRIs available in the US for treatment of depression include citalopram (*Celexa*, and others), escitalopram (*Lexapro*), fluoxetine (*Prozac*, and others), paroxetine (*Paxil*, and others) and sertraline (*Zoloft*).

FIRST-TRIMESTER USE — A case-control study in 9622 infants with major birth defects and 4092 controls found no significant association between use of SSRIs in early pregnancy and birth defects, except for a slightly increased incidence of anencephaly, craniosynostosis and omphalocele.² A similar study comparing 9849 infants who had birth defects with 5860 controls found no significant association between SSRI use in the first trimester and craniosynostosis, omphalocele or heart defects, but analyses of individual SSRIs found that use of sertraline was associated with septal defects and omphaloceles, and use of paroxetine was associated with right ventricular outflow tract obstruction.³ Positive findings can occur by chance in malformation studies when multiple comparisons are made, and in both of these studies the absolute risks of all of these defects were small.

Other studies also found an increased risk of cardiac defects associated with paroxetine use in early pregnancy, leading the FDA and Health Canada to warn against such use, and the FDA to classify the drug as category D (positive evidence of risk) for use during pregnancy. One case-control study, however, found that the increased risk of major cardiac malformations with paroxetine use in the first trimester was statistically sig-

nificant only in women who took more than 25 mg per day (the usual dose is 20 mg per day); for these women, the adjusted odds ratio was 3.07, with a 95% confidence interval that extended from 1.00 to 9.42.⁴ A study of 1174 first-trimester exposures to paroxetine ascertained from 8 teratology information services found that the risk of congenital cardiovascular defects was no greater than in a comparison group of unexposed women.⁵

THIRD-TRIMESTER USE — Infants born to mothers who took an SSRI in the third trimester have been reported to have a higher risk of requiring treatment in an intensive care unit, possibly related to a withdrawal reaction, and of developing persistent pulmonary hypertension.^{6,7} The possible neonatal withdrawal syndrome, which has usually been limited to feeding problems and jitteriness, but rarely has included convulsions and respiratory distress requiring intubation, has been associated particularly with paroxetine, which has the shortest half-life of the SSRIs.⁸⁻¹⁰

Persistent pulmonary hypertension, which occurs in 2 per 1000 live births, occurs in about one per 100 newborns exposed to an SSRI in the second half of pregnancy, possibly related to serotonin-related effects on cardiovascular development.¹¹ Persistent pulmonary hypertension can have serious consequences, including neurodevelopmental abnormalities and death.¹²

NEUROBEHAVIORAL DEVELOPMENT — **Animals** — Studies in rodent models have shown that increased extracellular serotonin concentrations can have adverse effects on the developing brain and cause changes in behavior, such as aggression, anxiety and depression, that may not become apparent until adulthood.¹³

Humans — One study from an information and counseling program for pregnant women compared the children of 55 mothers exposed to fluoxetine during pregnancy (one third of the women took the drug throughout pregnancy) with the children of 84 mothers who did not take an SSRI during pregnancy and were not depressed. The children were tested,

apparently once each, between the ages of 16 and 86 months (mean age at testing 33 months). There were no significant differences between the 2 groups in IQ or language development.¹⁴

A second study from the same program compared 40 mother-child pairs (including 18 that were in the first study) exposed to fluoxetine throughout pregnancy to 36 mothers who were not depressed and not treated and their children. Neurobehavioral testing of the children between 15 and 71 months (mean age of the exposed children at the time of evaluation was 28 months and that of the control children was 42 months) found no significant differences between the 2 groups in tests of cognition, language and temperament.¹⁵

A small study that followed infants to 40 months of age found that treatment with SSRIs during pregnancy was associated with subtle effects on the motor development of the offspring, such as tremulousness and inappropriate fine motor movements; the control group consisted of women who were also depressed but did not take medication.¹⁶

There are no studies available following children exposed to an SSRI during fetal development into adolescence.

CONCLUSION — SSRI use during the first trimester of pregnancy generally appears to have a low risk of causing congenital abnormalities, but the risk of cardiac abnormalities with paroxetine is unclear. Third trimester SSRI use can cause apparent withdrawal symptoms and persistent pulmonary hypertension in the offspring. The long-term effects of SSRI exposure during pregnancy on neurobehavioral development are unknown. The potential risks of exposure to SSRIs during pregnancy must be weighed against the risks of untreated depression. □

1. MK Bakker et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. *Br J Clin Pharmacol* 2008; 65:600.
2. S Alwan et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. *N Engl J Med* 2007; 356:2684.
3. C Louik et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007; 356:2675.
4. A Berard et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. *Birth Defects Res B Dev Reprod Toxicol*, 2007; 80:18.
5. A Einarson et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. *Am J Psychiatry* 2008; 165:749.
6. H Malm et al. Risks associated with selective serotonin reuptake inhibitors in pregnancy. *Obstet Gynecol* 2005; 106:1289.
7. CD Chambers et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006; 354:579.

8. EJ Sanz et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet* 2005; 365:482.
9. EL Moses-Kolko et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. *JAMA* 2005; 293:2372.
10. H Nordeng and O Spigset. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. *Drug Saf* 2005; 28:565.
11. JL Mills. Depressing observations on the use of selective serotonin-reuptake inhibitors during pregnancy. *N Engl J Med* 2006; 354:636.
12. PH Lipkin et al. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. *J Pediatr* 2002; 140:306.
13. X Borue et al. Developmental effects of SSRIs: lessons learned from animal studies. *Int J Devl Neuroscience* 2007; 25:341
14. I Nulman et al. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med* 1997; 336:258.
15. I Nulman et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. *Am J Psychiatry* 2002; 159:1889.
16. RC Casper et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. *J Pediatr* 2003; 142:402.

The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., Weill Medical College of Cornell University
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS, DRUG INFORMATION:
Susan M. Daron, Pharm.D.
Blaine M. Houst, Pharm.D.
Corinne E. Zanone, Pharm.D.
CONTRIBUTING EDITORS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein College of Medicine
ADVISORY BOARD:
Jules Hirsch, M.D., Rockefeller University
David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre
Richard B. Kim, M.D., University of Western Ontario
Gerald L. Mandell, M.D., University of Virginia School of Medicine
Hans Meinertz, M.D., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York University School of Medicine
SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard
ASSOCIATE EDITOR: Cynthia Macapagal Covey
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Manouchkathe Cassagnol, Pharm.D., St. John's University
PRODUCTION COORDINATOR: Cheryl Brown
ASSISTANT MANAGING EDITOR: Liz Donohue
MANAGING EDITOR: Susie Wong

EXECUTIVE DIRECTOR OF SALES: Gene Carbona
FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski
DIRECTOR OF MARKETING & COMMUNICATIONS: Joanne F. Valentino
VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. The content of The Medical Letter is controlled by the Editor, who declares no conflict. The members of the Advisory Board are required to disclose any potential conflict of interest.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter, Inc.
1000 Main Street
New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
Web Site: www.medicalletter.org
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$98; 2 years - \$167;
3 years - \$235. \$49 per year for students, interns, residents and fellows in the US and Canada.
CME: \$49 for 26 credits.

E-mail site license inquiries to:

info@medicalletter.org or call 800-211-2769 x315.
Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

Copyright 2008. ISSN 1523-2859